Company: TouchDown Therapeutics
Job title: Vice President Immunology and Safety
Roberto Calcedo has PhD in Biology from University of Basque Country, Spain. He is member of the scientific board of Human Gene Therapy journal and member of the Immune response to Gene and cell therapy committee (ASGCT). He has been working in gene therapy since 2001 and was instrumental in the discovery of a new family of AAV vectors, including AAV8, AAV9, AAVrh10, currently used the clinic. He worked in the Gene Therapy Program (GTP) at the University of Pennsylvania for 19 years. He oversaw the GTP Immunology Core activities which focuses on humoral and cellular immune responses to viral vectors and transgene products in animal models and in subjects enrolled in phase I clinical trials. In his current role as VP of Immunology at TDTx he conducts research and development on mechanisms of immune activation and immune modulation in the settings of AAV gene therapy. He is the author of more than 60 peer-reviewed scientific publications.
Live Q&A – Ask the speakers your questions 11:30 am
day: Day Two
Compartmentalization of Immune Response After AAV Gene Therapy 11:00 am
• Blood is not the best surrogate to study T-cell responses to AAV vectors • T-cell responses can be found in the liver but not in blood after CNS and IV delivery of AAV Vectors • Discuss whether T-cell responses in the liver are beneficial to induce tolerance in AAV vectorsRead more
day: Day Two